Reviewing Revolutions Medical (OTCMKTS:RMCP) & Cardiovascular Systems (NASDAQ:CSII)

Revolutions Medical (OTCMKTS:RMCPGet Rating) and Cardiovascular Systems (NASDAQ:CSIIGet Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.


This table compares Revolutions Medical and Cardiovascular Systems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Revolutions Medical N/A N/A N/A
Cardiovascular Systems -16.40% -15.51% -12.12%

Insider & Institutional Ownership

91.7% of Cardiovascular Systems shares are owned by institutional investors. 10.5% of Revolutions Medical shares are owned by company insiders. Comparatively, 3.8% of Cardiovascular Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Revolutions Medical has a beta of -0.43, indicating that its share price is 143% less volatile than the S&P 500. Comparatively, Cardiovascular Systems has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

Earnings & Valuation

This table compares Revolutions Medical and Cardiovascular Systems’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Revolutions Medical N/A N/A N/A N/A N/A
Cardiovascular Systems $236.22 million 2.50 -$36.93 million ($1.00) -14.08

Revolutions Medical has higher earnings, but lower revenue than Cardiovascular Systems.

Analyst Recommendations

This is a breakdown of recent recommendations for Revolutions Medical and Cardiovascular Systems, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revolutions Medical 0 0 0 0 N/A
Cardiovascular Systems 1 0 1 0 2.00

Cardiovascular Systems has a consensus price target of $20.00, suggesting a potential upside of 42.05%. Given Cardiovascular Systems’ higher possible upside, analysts clearly believe Cardiovascular Systems is more favorable than Revolutions Medical.


Cardiovascular Systems beats Revolutions Medical on 5 of the 9 factors compared between the two stocks.

About Revolutions Medical

(Get Rating)

Revolutions Medical Corporation, a development stage company, is engaged in the design, development, and commercialization of auto retractable vacuum safety syringes in the United States and internationally. The company develops RevVac auto retractable vacuum safety syringe, which is designed to reduce accidental needle stick injuries and lower the spread of blood borne diseases. It is also developing a suite of magnetic resonance imaging software tools consisting of RevColor, Rev3D, RevDisplay, and RevScan that are designed to enhance general diagnostic confidence through education and research use. The company sells its products to acute care hospitals, alternate care facilities, doctors' offices, clinics, emergency centers, surgical centers, convalescent hospitals, veterans administration facilities, military organizations, public health facilities, and prisons through distributors. Revolutions Medical Corporation was founded in 1996 and is headquartered in Charleston, South Carolina.

About Cardiovascular Systems

(Get Rating)

Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.

Receive News & Ratings for Revolutions Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolutions Medical and related companies with's FREE daily email newsletter.